Skip to main content
. Author manuscript; available in PMC: 2010 Aug 2.
Published in final edited form as: Methods Mol Biol. 2010;623:325–339. doi: 10.1007/978-1-60761-588-0_21

Fig. 2.

Fig. 2

Immunosuppressive molecules expressed by DCs that can be targeted by RNAi for cancer immunotherapy. A20, SOCS1, and Tyro3/Axl/Mer suppress the antigen presentation and T cell activation capacity of DCs. IDO, PD-L1, DIgR2, Notch ligands, and FasL directly inhibit T cell proliferation, function, or survival. CCL17 and CCL22 mediate the recruitment of Treg cells to the tumor. miR-155 and miR-146a are predicted to be suppressive miRNAs which inhibit DC function